Allen Kaplan to Aged
This is a "connection" page, showing publications Allen Kaplan has written about Aged.
Connection Strength
0.140
-
Omalizumab response in patients with chronic idiopathic urticaria: Insights from the XTEND-CIU study. J Am Acad Dermatol. 2018 04; 78(4):793-795.
Score: 0.048
-
Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol. 2013 Jul; 132(1):101-9.
Score: 0.036
-
The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria. J Allergy Clin Immunol. 2018 03; 141(3):1138-1139.e7.
Score: 0.012
-
Omalizumab substantially improves dermatology-related quality of life in patients with chronic spontaneous urticaria. J Eur Acad Dermatol Venereol. 2017 Oct; 31(10):1715-1721.
Score: 0.012
-
Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013 Mar 07; 368(10):924-35.
Score: 0.009
-
Safety and tolerability of the direct renin inhibitor aliskiren in combination with angiotensin receptor blockers and thiazide diuretics: a pooled analysis of clinical experience of 12,942 patients. J Clin Hypertens (Greenwich). 2011 Jul; 13(7):506-16.
Score: 0.008
-
Safety and tolerability of the direct renin inhibitor aliskiren: a pooled analysis of clinical experience in more than 12,000 patients with hypertension. J Clin Hypertens (Greenwich). 2010 Oct; 12(10):765-75.
Score: 0.007
-
Histologic studies of chronic idiopathic urticaria. J Allergy Clin Immunol. 1983 Feb; 71(2):177-83.
Score: 0.004
-
A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria. J Allergy Clin Immunol. 1999 Nov; 104(5):1071-8.
Score: 0.003